Loading
Life sciences · Journal article
Journal of Hepato-biliary-pancreatic Sciences · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Gallbladder cancer is a rare but aggressive malignancy with poor prognosis even after curative-intent surgery. Conventional survival estimates provide fixed probabilities from diagnosis and fail to reflect the evolving prognosis of patients who have already survived several years. Conditional survival (CS) offers time-updated prognostic information, but evidence in gallbladder cancer remains limited. METHODS: We retrospectively analyzed 641 patients who underwent curative-intent resection for gallbladder cancer at a tertiary referral center (2005-2019). Five-year conditional overall survival (COS) and conditional recurrence-free survival were estimated up to 5 years postoperatively. Analyses were stratified by age, stage, comorbidity, surgical extent, and adjuvant therapy. RESULTS: Baseline 5-year COS was 69.4% and increased to 74.0% among patients surviving 5 years. Stage III patients showed the largest improvement (45.9%-69.4%), whereas Stage I patients remained stable. In Stage II-III disease, extended cholecystectomy was associated with improved COS (63.2%-74.3%), while simple cholecystectomy showed a decline (65.7%-48.0%). Adjuvant therapy was associated with greater COS improvement (50.4%-69.2%) than no adjuvant therapy. Older patients (≥ 70 years) and those with diabetes showed poorer outcomes. CONCLUSION: CS provides a dynamic framework for prognostication in gallbladder cancer and may support risk-stratified follow-up.